Target intelligence / Profile preview

L-type calcium channel subunit alpha-1C (CaV1.2) (CaV1.2)

Target
CaV1.2
Molecular classification
Ion channel, Voltage-gated calcium channel
01

Overview

L-type calcium channel subunit alpha-1C (CaV1.2) is the dominant voltage-gated calcium channel expressed in vascular smooth muscle cells and is responsible for the major influx of Ca²⁺ that triggers muscle contraction, gene expression, and cellular signaling[2][3][6]. CaV1.2 operates as a heteromeric complex and is essential for regulating vascular tone and arterial contractility; dysfunction or overactivation contributes to disorders such as hypertension and vascular complications of diabetes[2][3][6]. CaV1.2 is therapeutically targeted by calcium channel blockers (such as amlodipine and nifedipine) used in the management of hypertension and cardiovascular diseases by inhibiting channel-mediated calcium entry and thus reducing vascular smooth muscle contraction[2][3][6].

Other names
L-type calcium channelVoltage-gated calcium channel subunit alpha-1CCaV1.2 channelLTCCCACNA1C
02

Mechanism of action

Calcium channel blockade (prevention of Ca²⁺ influx); Inhibition of vasoconstriction/contraction

03

Biological functions

Regulation of vascular smooth muscle contractionSignal transductionControl of myogenic toneRegulation of gene expression
04

Disease associations

Cardiovascular diseaseHypertensionDiabetes (vascular complications)Vascular dysfunction
05

Safety considerations

HypotensionBradycardiaEdemaNegative inotropy in heart failure
06

Interacting drugs

Amlodipine

3 more in the full profile.

07

Biomarkers

CaV1.2 expression levels in vascular smooth muscle (experimental/research)

Beyond the preview

Go deeper on L-type calcium channel subunit alpha-1C (CaV1.2) (CaV1.2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-type calcium channel subunit alpha-1C (CaV1.2) (CaV1.2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call